智飞生物
(300122)
| 流通市值：290.92亿 | | | 总市值：492.40亿 |
| 流通股本：14.14亿 | | | 总股本：23.94亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 2,566,465,559.45 | 3,069,009,417.19 | 2,700,466,763.66 | 3,263,949,292.31 |
| 衍生金融资产 | 2,355,610.36 | - | - | - |
| 应收票据及应收账款 | 13,517,972,648.94 | 14,645,413,281.08 | 16,272,763,249.18 | 21,391,675,746.63 |
| 应收账款 | 13,517,972,648.94 | 14,645,413,281.08 | 16,272,763,249.18 | 21,391,675,746.63 |
| 预付款项 | 28,432,594.6 | 40,406,471.57 | 45,612,057.91 | 59,640,771.04 |
| 其他应收款合计 | 11,320,897.76 | 9,326,586.33 | 10,952,388.39 | 10,300,183.84 |
| 存货 | 21,014,568,347.64 | 21,905,281,179.72 | 22,218,088,029.07 | 20,692,520,989.75 |
| 其他流动资产 | 6,242,420.34 | 5,927,560.01 | 8,106,399.42 | 2,973,707.68 |
| 流动资产合计 | 37,147,358,079.09 | 39,675,364,495.9 | 41,292,988,542.93 | 45,458,060,346.55 |
| 非流动资产: | | | | |
| 其他权益工具投资 | 291,000,000 | 291,000,000 | 295,000,000 | 295,000,000 |
| 投资性房地产 | 315,504.46 | 361,835 | 176,638.52 | 198,972.23 |
| 固定资产 | 4,358,489,204.98 | 4,431,003,448.31 | 4,337,774,955.95 | 3,621,578,779.29 |
| 在建工程 | 831,511,209.77 | 853,311,001.42 | 1,006,182,134.18 | 1,531,016,046.65 |
| 使用权资产 | 20,638,561.98 | 23,902,831.04 | 26,925,597.4 | 30,326,015.33 |
| 无形资产 | 550,318,243.66 | 563,712,830.38 | 300,263,604.23 | 300,647,626.01 |
| 开发支出 | 1,362,412,117.73 | 1,254,685,404.35 | 1,419,295,740.96 | 1,200,224,519.38 |
| 商誉 | 19,279,096.95 | 19,279,096.95 | 19,279,096.95 | 19,279,096.95 |
| 长期待摊费用 | 89,139,998.55 | 92,509,128.2 | 95,195,307.75 | 85,783,111.73 |
| 递延所得税资产 | 1,103,050,758.71 | 956,487,466.21 | 928,497,256.49 | 812,879,146.91 |
| 其他非流动资产 | 163,760,463.67 | 178,702,305.69 | 188,034,960.04 | 354,580,927.42 |
| 非流动资产合计 | 8,789,915,160.46 | 8,664,955,347.55 | 8,616,625,292.47 | 8,251,514,241.9 |
| 资产总计 | 45,937,273,239.55 | 48,340,319,843.45 | 49,909,613,835.4 | 53,709,574,588.45 |
| 流动负债: | | | | |
| 短期借款 | 13,964,455,677.63 | 14,666,465,750.25 | 11,901,908,557.91 | 8,649,020,971.55 |
| 衍生金融负债 | - | 1,928,650.82 | - | - |
| 应付票据及应付账款 | 636,860,737.11 | 1,950,022,939.26 | 5,419,560,049.74 | 12,160,670,010.97 |
| 其中：应付票据 | 3,133,764 | - | - | - |
| 应付账款 | 633,726,973.11 | 1,950,022,939.26 | 5,419,560,049.74 | 12,160,670,010.97 |
| 预收款项 | 1,406,328.64 | 3,434,374.74 | 23,891,533.35 | 23,617,012.78 |
| 合同负债 | 14,290,268.71 | 11,629,221.91 | 11,869,634.92 | 10,075,699.57 |
| 应付职工薪酬 | 40,868,689.68 | 25,466,419.04 | 223,361,054.13 | 55,094,650.61 |
| 应交税费 | 122,522,558.49 | 183,436,791.64 | 394,462,353.73 | 307,522,291.03 |
| 其他应付款合计 | 238,571,453.66 | 272,983,659.8 | 372,431,976.47 | 364,917,238.26 |
| 一年内到期的非流动负债 | 150,826,079.81 | 148,191,173.43 | 93,640,944.12 | 78,118,654.26 |
| 流动负债合计 | 15,169,801,793.73 | 17,263,558,980.89 | 18,441,126,104.37 | 21,649,036,529.03 |
| 非流动负债: | | | | |
| 长期借款 | 276,626,983.65 | 279,440,292.91 | 347,588,788.71 | 334,507,804.14 |
| 租赁负债 | 12,082,249.38 | 16,706,979.02 | 15,447,210.27 | 18,953,997.75 |
| 递延收益 | 204,706,881.62 | 210,696,781.45 | 230,402,811.36 | 212,065,989.18 |
| 递延所得税负债 | 40,411,513.93 | 44,317,994.36 | 44,309,512.59 | 53,368,486.82 |
| 非流动负债合计 | 533,827,628.58 | 551,162,047.74 | 637,748,322.93 | 618,896,277.89 |
| 负债合计 | 15,703,629,422.31 | 17,814,721,028.63 | 19,078,874,427.3 | 22,267,932,806.92 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 2,393,789,747 | 2,393,789,747 | 2,393,789,747 | 2,393,789,747 |
| 盈余公积 | 1,196,894,873.5 | 1,196,894,873.5 | 1,196,894,873.5 | 954,144,855.81 |
| 未分配利润 | 26,642,959,196.74 | 26,934,914,194.32 | 27,240,054,787.6 | 28,093,707,178.72 |
| 归属于母公司股东权益合计 | 30,233,643,817.24 | 30,525,598,814.82 | 30,830,739,408.1 | 31,441,641,781.53 |
| 股东权益合计 | 30,233,643,817.24 | 30,525,598,814.82 | 30,830,739,408.1 | 31,441,641,781.53 |
| 负债和股东权益合计 | 45,937,273,239.55 | 48,340,319,843.45 | 49,909,613,835.4 | 53,709,574,588.45 |
| 公告日期 | 2025-08-19 | 2025-04-22 | 2025-04-22 | 2024-10-26 |
| 审计意见(境内) | | | 标准无保留意见 | |